Finally, we examined the FGFR-TACC3 fusion, FGFR amplified bladder cancer RT112 cell line that is sensitive to BGJ398 (infigratinib) and found a similar synergy with prednisone in a xenograft model (Fig. 6e) and a suppression of bypass RTK signaling (Supplementary Fig. 18). Here, TACC3 is linked to urinary bladder cancer.